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ABSTRACT
Objective: To estimate the cost-effectiveness of second-line pharmacological treatments in patients
with acromegaly resistant to first-generation somatostatin analogues (FG SSA) from the Spanish
National Health System (NHS) perspective.
Methods: A Markov model was developed to analyze the cost-effectiveness of pegvisomant and
pasireotide in FG SSA-resistant acromegaly, simulating a cohort of patients from the treatment begin-
ning to death. Treatment with pegvisomant or pasireotide was compared to FG SSA retreatment.
Efficacy data were obtained from clinical trials and utilities from the literature. Direct health costs
were obtained from Spanish sources (€2018).
Results: The Incremental Cost Effectiveness Ratio (ICER) of pegvisomant vs. FG SSA was €85,869/
Quality-adjusted life years (QALY). The ICER of pasireotide vs. FG SSA was €551,405/QALY. The ICER
was mainly driven by the incremental efficacy (4.41 QALY for pegvisomant vs. FG SSA and 0.71 QALY for
pasireotide vs. FG SSA), with a slightly lower increase in costs with pegvisomant (€378,597 vs. FG SSA)
than with pasireotide (€393,151 vs. FG SSA).
Conclusion: The ICER of pasireotide compared to FG SSA was six times higher than the ICER of
pegvisomant vs. FG SSA. Pegvisomant is a more cost-effective alternative for the treatment of acrome-
galy in FG SSA-resistant patients in the Spanish NHS.
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Acromegaly is a disease caused by an excessive secretion of
growth hormone (GH), generally caused by the presence of
a pituitary adenoma. It is included in the group of rare
diseases due to its low prevalence. European epidemiologi-
cal data show an incidence rate of 0.2–1.1 cases per 100,000
and a prevalence rate of 2.8–13.7 cases per 100,000 inhabi-
tants [1]. According to the Spanish Acromegaly Registry, the
estimated prevalence rate of acromegaly in Spain is 36
cases per million, ranging from 15.7 to 75.8 depending on
the geographic area [2] with an increased prevalence in
women (60.8%) [3].
The disease develops insidiously, causing an important
delay in diagnosis. The mean age at diagnosis is 45.5 years,
with a mean time of 6 years from the onset of the first
symptoms of acromegaly to diagnosis [3]. The clinical mani-
festations of acromegaly depend on growth hormone (GH)
and insulin-like growth factor 1 (IGF-1) levels, the patient’s
age, the size of the tumor and the delay in diagnosis. Facial
changes (frontal prominence and prognathism), acral growth,
hypertension, symptoms of hyperglycemia, cardiomyopathy,
heart failure, and sleep apnoea are generally observed [4].
The objectives of acromegaly treatment are: to diminish the
tumor mass; normalize IGF-1 and GH levels; control symptoms
and comorbidities; improve quality of life; and prevent pre-
mature mortality due to the disease [4].
There are three therapeutic approaches for the treatment of
acromegaly: surgery, pharmacologic therapy and radiotherapy
[4,5]. Surgery is the main first-line treatment. Pharmacological
treatment is used as a primary treatment (in patients for whom
surgery is not suitable or is not effective or in the interim period
until radiotherapy is completely effective) or if surgery fails.
First-line pharmacological treatment is based on first-line soma-
tostatin analogues (FG SSA, octreotide, and lanreotide) [2,4,6].
Pegvisomant (GH receptor antagonist) [7] or pasireotide (sec-
ond generation somatostatin analogue) [8] is used when the
patient does not respond adequately to or does not tolerate FG
SSA (second-line pharmacological treatment) [9]. Although
there are not comparative head-to-head data available, results
of their respective clinical trials show that the efficacy (both in
terms of biochemical and tumor control) and safety profile of
pegvisomant and pasireotide differs considerably [10,11].
The objective of this analysis was to estimate the cost-
effectiveness of second-line pharmacological treatments (peg-
visomant or pasireotide) in patients with acromegaly resistant
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to first-generation somatostatin analogues (FG SSA) from the
perspective of the Spanish National Health System (NHS).
Therefore, it aims to provide information to support the deci-
sion-making process regarding the selection of second-line
acromegaly treatments from the perspective of the Spanish
National Health System (NHS).
2. Methods
2.1. Summary of the economic model
A Markov model was used to simulate the lifetime disease pro-
gression of a cohort of 1,000 patients with acromegaly requiring
second-line pharmacological treatment. Three mutually exclu-
sive health states were included: controlled patient, uncontrolled
patient, and death. Patients transition in six-month cycles based
on the different transition probabilities calculated using pub-
lished clinical trials (see below).
The alternative treatments evaluated were FG SSA (octreo-
tide LAR or lanreotide ATG), pasireotide, and pegvisomant. It
was not possible to switch treatment from pasireotide to
pegvisomant or vice versa in the absence of available data
to support this possibility. Combination treatment (off-label
use) was not considered in the model.
The model was built using TreeAge Pro 2018, TreeAge
Software, Williamstown, MA, USA. Figure 1 shows the decision
tree used in the model for the three states and alternatives
considered.
Live years gained (LYG), quality-adjusted life years (QALYs),
and the associated costs for each alternative were calculated.
Incremental cost-effectiveness ratios (ICER) of the comparisons
were calculated using the formula:
ICER ¼ Cost of Alternative A  Cost of Alternative B
QALYs of Alternative A  QALYs of Alternative B
2.2. Analysis perspective and discount
The analysis was performed from the perspective of the
Spanish NHS. Only direct health-care costs (cost of medication,
management of adverse events, follow-up and management
of comorbidities) were considered.
For the base case, a 3% discount was applied to both costs
and benefits (Life Years Gained [LYG] and QALYs) [12].
2.3. Time horizon
The model was developed to cover the lifetime progression of
the disease. Taking into account that the mean diagnosis age
of acromegaly in Spain is 45 years [2] and adjusting for life
Figure 1. Decision tree model in patients with acromegaly requiring second-line pharmacological treatment.
Article highlights
● In patients not fully controlled with first-generation somatostatin
analogues (FG SSA), it is important to take into account not only
the efficacy and safety data from pivotal clinical trials, but also to the
cost-effectiveness evidence to support the decision-making process
in the selection of treatment alternatives.
● The Incremental Cost Effectiveness Ratio (ICER) of pegvisomant vs. FG
SSA was €85,869/Quality-adjusted life years (QALY).
● The ICER of pasireotide vs. FG SSA was €551,405/QALY, six times higher
than the ICER of pegvisomant vs. FG SSA.
● The difference in both ICERs wasmainly driven by the incremental efficacy
(4.41 QALY for pegvisomant vs. FG SSA and 0.71 QALY for pasireotide vs.
FG SSA), with a slightly lower increase in costswith pegvisomant (€378,597
vs. FG SSA) than with pasireotide (€393,151 vs. FG SSA).
● Pegvisomant is a more cost-effective monotherapy alternative for the
treatment of acromegaly in FG SSA-resistant patients in the Spanish
NHS.
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expectancy according to age and gender [13], time horizon
was set to 42 years for the base case analysis.
2.4. Patient populations and treatments
The cohort of patients was defined based on baseline char-
acteristics of the clinical trials analyzed [10,11]. These studies
included adult patients with inadequately controlled acrome-
galy (high levels of serum GH and/or IGF-1) after surgical and
FG SSA treatment (Table 1).
The mortality rate derived from each state of health was
obtained based on the general mortality data adjusted by age
in the Spanishpopulation [13]. From this data, and as described in
the literature [14], we assumed a death relative risk ratio of 1.1
and 2.5 for the controlled and uncontrolled acromegaly patients,
respectively.
The mean dose, efficacy, and clinically significant adverse
events of each treatment were extracted from clinical trials for
pegvisomant [11], pasireotide [10] and FG SSA [10] (Table 1). In
the base case, the efficacy rate obtained using the mean study
dose was used. The efficacy of FG SSA was 0% since the
baseline population considered in the model is resistant to
this medication, and in line with the efficacy results of the
comparator arm (FG SSA) in the pasireotide clinical trial used
in the model [10] (Table 1). Efficacy (i.e. controlled patients)
was defined as a mean GH concentration < 2.5 µg/L and/or
normalized IGF-1 concentration (between the upper and the
lower limits of normality) for FG SSA and pasireotide [15].
Pegvisomant efficacy was defined in terms of normalized
IGF-1 concentration only, since, according to its mechanism
of action, it does not reduce GH levels [11,16].
Although the maximum dose of pegvisomant is 30 mg/day
according to its label [7], the model assumed the efficacy
range shown in the clinical trial (maximum dose studied: 20
mg/day) (Table 1). The mean dose considered in the model (15
mg/day) is in line with the mean dose used in Spanish patients
according to the real-world study ACROSTUDY (15.5 mg/day)
[15]. It was assumed that the efficacy shown in the pegviso-
mant clinical trial at 12 weeks is maintained at 24 weeks, in
order to allow comparison with the pasireotide clinical trial
[10]. This assumption is plausible considering the long-term
treatment outcomes observed in ACROSTUDY [15].
2.5. Estimation of utilities
QALYs were calculated taking into account the quality of life
(“utility“) and the LYG in each state of health. The reduction in
the quality of life (”disutility”) produced by the treatment-
related adverse events was also considered. The utility and
disutility values applied in the model were obtained from the
literature [17–20] (Table 2).
Table 1. Description of the studies, mean dose, efficacy, and safety results considered in the model.














ATG 120 mg every
28 days).
Octreotide LAR (75% of
patients): 30 mg/28 days
Lanreotide ATG (25% of
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0% Tumour increase: 1.52%
Hyperglycaemia (grade ≥ 3): 0%
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9.60%
Diarrhoea:
(grade ≥ 3): 0%;























(grade ≥ 3): 0%
(grade < 3): 6.25%
FG SSA: first-generation somatostatin analogues; LAR: long-acting release; ATG: autogel.
aControl of IGF-I and GH levels; bControl of IGF-I levels.
Bold values highlight the efficacy rates at mean dose used in the model.
Table 2. Utility values (quality of life) used in the model.
Utility value Source
Health states
Controlled acromegaly patient 0.81000 [19]
Uncontrolled acromegaly patient 0.64400
Death 0 [12]
Adverse events (disutilities)
Tumour increase −0.14955 [19]





aIt is assumed that both events are reversible and of short duration so they
do not translate into a decrease in utility
bIt is assumed that each episode of diarrhea lasts for 7 days and that diarrhea
adverse events are equally distributed between moderate and severe diarrhea.
Bold text is used for headings.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH 107
2.6. Estimation of resources and costs
The estimation of costs considered in themodel was made using
published Spanish official rates (Table 1 in Appendix). Diagnostic-
related Groups (DRGs) method was used for the allocation of
resources or processes.
Medication costs:
Medication costs include both pharmacological costs and drug
administration-related costs, if applicable. Ex-factory prices (EFP)
were used to calculate the cost per mg, and applicable official
discounts were applied (−4% for pasireotide, −7.5% for pegviso-
mant 25 and 30 mg and −15% for lanreotide and pegvisomant 10,
15, and 20 mg). Medication cost per cycle was calculated with the
cost per mg and the mean dose (Table 1) for each treatment
alternative (Table 3).
In cases where the cost per mg of the drug was not linear
(lanreotide), a conservative approach was applied and the presen-
tation with the lowest price per milligram was used. In the case of
pasireotide, since the clinical trial comprises doses of 40 mg and 60
mg, both costs were used. Cost of FG SSA treatment was calculated
considering the proportion of use of octreotide and lanreotide in
the clinical trial [10] (Table 1).
Table 3. Costs per cycle (6 months) used in the model (€2018) [5,13,16,20,24–28]. Percentage of the unit cost imputed to each item is shown in column ‘%’. Inthe
case of pharmacological costs, the percentages reflect the proportion of drug used in the studies considered in the model (see Table 1), and unit costs are calculated
considering the mean dose and the dosing schedule in the label (see Table 1).
Item % Units Unit cost (€) Total cost (€)
MEDICATION COSTS
Pharmacological costsa
Pegvisomant 100% 2,738.48 mg 5.5063 15,078.89
Octreotide 75% 195.54 mg 17.37 4,043.32
Lanreotide 25% 782.14 mg 7.65
Pasireotide vial 40 mg 50% 260.71 mg 57.60 15,695.89
Pasireotide vial 60 mg 50% 391.07 mg 41.87
Costs of intramuscular administrationb 158.41
Nursing visit cost 100% 6 26.40 158.41
COSTS OF TREATMENT OF ADVERSE EVENTSb
Increased tumor mass 3,542.29
Specialist visit 70% 2 96.16 134.63
Cranial MRI 100% 2 323.52 647.05
Surgical treatment 30% 1 9,202.05 2,760.61
Liver enzyme abnormalities 229.38
Specialist visit 100% 2 96.16 192.32
Complete Blood Count 100% 2 4.72 9.44
ALT 100% 2 1.28 2.55
AST 100% 2 1.28 2.55
Bilirubin 100% 2 1.73 3.46
Gamma GT 100% 2 1.68 3.36
Alkaline phosphatase 100% 2 2.87 5.74
LDH 100% 2 4.98 9.96
Cholelithiasis 342.50
Hospitalisation 30% 1 606.44 181.93
Specialist visit 70% 2 96.16 134.63
Complete Blood Countc 70% 2 4.72 6.61
ALTc 70% 2 1.28 1.79
ASTc 70% 2 1.28 1.79
Bilirubinc 70% 2 1.73 2.42
Gamma GTc 70% 2 1.68 2.35
Alkaline phosphatasec 70% 2 2.87 4.02
LDHc 70% 2 4.98 6.97
Hyperglycaemia (AE grade ≥ 3) [22,23]d 2,584.33
FOLLOW-UP COSTSb
Pegvisomant
MRI (first 2 years) 100% 1 323.52 323.52
FG SSA and pasireotide
MRI (first 2 years) 100% 0.5 323.52 161.76
Liver ultrasound 100% 0.5 120.78 60.39
COMORBIDITY TREATMENT COSTS
Moderate hypertension [31] 691.14




Sleep apnoea [27] 466.49
MRI: magnetic resonance imaging;FG SSA: first-generation somatostatin analogues (octreotide, lanreotide). #) in 100% of outpatients (in hospitalised patients,
hospitalisation already includes this test) (ǂ) Cost allocated in the first treatment cycle only.
aObtained from ex-factory prices
bCosts are the mean of the official rates in the Spanish regional health systems (Table 1 in Appendix)
cIn 100% of outpatients (in hospitalized patients, hospitalization already includes this test)
dCost allocated in the first treatment cycle only.
Bold text is used for headings and total cost of each category.
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The cost of a nursing visit was used as an estimation of the cost
of intramuscular administration (Table 3).
Follow-up costs:
Only differential follow-up costs derived from each treatment alter-
native were taken into account as shown in Table 3. Differential
follow-up costs identified were the cost of liver ultrasound and
resonance imaging, according to international guidelines [5] and
expert’s opinion.
Adverse events management costs:
Adverse events management costs were calculated adopting a
microcosting approach [21]. Unit costs are the mean unit costs of
the official rates in the Spanish regional health systems (Table 1 in
Appendix).
The cost for hyperglycemia (grade ≥3) was calculated from the
mean cost of grade 3 or 4 hyperglycaemic events due to pharma-
cological treatment obtained from the literature [22] and the
Spanish Ministry of Health statistics [23] (Table 3). It was assumed
that hyperglycaemic adverse events take place at the beginning of
treatment. Therefore, its associated costs and disutility values were
allocated in the first cycle only.
Comorbidity management costs:
The comorbidities considered in the model were the most pre-
valent in patients with acromegaly [24]: hypertension, arrhythmia,
glucose-homeostasis alterations, diastolic/systolic dysfunction,
and sleep apnoea. For the prevalence of cardiac comorbidities
in patients with controlled/uncontrolled acromegaly, we used a
study that addresses this in the same population of patients and
considered the prevalence in controlled patients to be the same
as in the control group in that study [25] (Table 2 in Appendix). In
patients with uncontrolled acromegaly, a higher prevalence was
considered according to the literature [25,26] (Table 2 in
Appendix). Comorbidity management costs were obtained from
the literature [27–31] (Table 3).
2.7. Sensitivity analyses
The following univariate sensitivity analyses (SA) were per-
formed in order to analyze the influence of the efficacy and
costs variables in the results obtained in the model:
● SA 1: A dose titration was considered instead of using
clinical trial mean doses. Patients started treatment with
the lowest dose (10 mg/day pegvisomant; 40 mg/month
pasireotide) and increased the dose in case of lack of
efficacy (in increments of 5 mg pegvisomant; 20 mg
pasireotide) up to the maximum dose (30 mg/day peg-
visomant; 60 mg/month pasireotide).
● SA 2: 100% patients in the somatostatin analogue alter-
native were treated with octreotide.
● SA 3: 100% patients in the somatostatin analogue alter-
native were treated with lanreotide.
● SA 4: Pasireotide efficacy was defined in terms of normal-
ization of IGF-1 levels rather than normalization of IGF-1
and GH levels.
● SA 5: A 10% increase in the efficacy of pegvisomant was
assumed to verify the influence of this variable.
● SA 6: The specific disutility value of diabetes in women
(−0.23) obtained from the literature [18], was used to
verify the influence of this variable.
● SA 7: The efficacy and safety of pegvisomant in a real-
world study was used [32]. Since there are not real-world
efficacy data for pasireotide, at least in a study with
sufficient methodological quality, the efficacy of pasireo-
tide in clinical trial was considered (Table 1).
● SA 8: An analysis with no discount was performed, in
accordance with the recommendations of the Spanish
economic evaluation guideline [12].
● SA 9: An analysis with a 5% discount was performed, in
accordance with the recommendations of the Spanish
economic evaluation guideline [12].
● SA 10–12: A time horizon of 5, 10, and 15 years was
considered to verify the effect of this variable.
In addition to these univariate analyses, a probabilistic sensi-
tivity analysis (PSA) was performed using a Monte Carlo
methodology [33]. One thousand simulations were carried
out, taking into account the different distributions of the
variables. Costs were described by gamma distributions and
efficacies by beta distributions. The α and λ parameters of the
gamma distributions and the α and β of the beta distributions
were obtained from the means and standard deviations
of each variable using the moments method (Table 3 in
Appendix).
3. Results
3.1. Base case and deterministic sensitivity analyses
Table 4 shows the results of costs and QALYs for each treatment
alternative in the base case scenario. Pegvisomant treatment ver-
sus FG SSA treatment had an incremental benefit of 5.15 life years
gained (LYG) and 4.41QALYswith an incremental cost of €378,597.
Therefore, the ICER of pegvisomant versus FG SSA was €73,514/
LYG and €85,869/QALY (Table 4).
Table 4. Results of the cost-effectiveness model, base case. Time horizon: Lifetime.
Item Pegvisomant Pasireotide FG SSA Pegvisomant vs FG SSA Pasireotide vs FG SSA
Costs (€) 629,247.95 643,801.71 250,650.09 378,597.86 393,151.62
Treatment costs 568,158.52 535,102.58 139,108.52 429,050.00 395,994.06
Follow-Up costs 1,100.40 2,608.02 2,541.77 −1,441.37 66.25
Comorbidity management costs 56,964.15 92,900.71 103,837.92 −46,873.77 −10,937.21
Adverse event management costs 3,024.88 13,190.40 5,161.88 −2,137.00 8,028.52
Effectiveness (QALYs) 14.505 10.809 10.096 4.409 0.713
ICER (€/QALY) 85,869.32 551,405
QALY: quality-adjusted life years; FG SSA: first-generation somatostatin analogues (octreotide, lanreotide).
Bold values are used to highlight total value in each category.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH 109
According to the deterministic sensitivity analyses, a titration
dosing of pegvisomant (SA 1) increased its ICER to €88,490/QALY
(Table 5). Conversely, when compared to lanreotide (SA 3), peg-
visomant ICER decreased to €71,344/QALY (Table 5). Taking into
account the efficacy and safety data in real clinical practice (SA 7),
pegvisomant ICER increased to €93,696/QALY (Table 5).
Pasireotide treatment versus FG SSA treatment showed an
incremental benefit of 1.20 life years gained (LYG) and 0.71
QALYs with an incremental cost of €393,151 (Table 4). Therefore,
the ICER of pasireotide versus FG SSA was €327,626/LYG and
€551,405/QALY (Table 4).
Table 5. Results of the cost-effectiveness model, univariate sensitivity analyses.
Pegvisomant vs FG SSA Pasireotide vs FG SSA
SA 1
(Dose titration)
Incremental cost €390,159 €410,799
Incremental effectiveness 4.409 QALY 0.714 QALY
ICER €88,490/QALY €575,686/QALY
SA 2
(100% octreotide as FG SSA)
Incremental cost €399,944 €414,498
Incremental effectiveness 4.409 QALY 0.714 QALY
ICER €90,709/QALY €580,869/QALY
SA 3
(100% lanreotide as FG SSA)
Incremental cost €314,559 €329,113
Incremental effectiveness 4.409 QALY 0.714 QALY
ICER €71,344/QALY €461,213/QALY
SA 4
(Pasireotide efficacy in IGF-1 levels)
Incremental cost €378,598 €396,165
Incremental effectiveness 4.409 QALY 1.119 QALY
ICER €85,868/QALY €354,068/QALY
SA 5
(10% increase in pegvisomant efficacy)
Incremental cost €381,806 €393,152
Incremental effectiveness 4.934 QALY 0.714 QALY
ICER €77,375/QALY €550,955/QALY
SA 6
(Diabetes disutility in women)
Incremental cost €378,598 €393,152




Incremental cost €376,192 €393,152




Incremental cost €590,928 €610,550




Incremental cost €292,248 €314,413
Incremental effectiveness 3.219 QALY 0.500 QALY
ICER €90,784/QALY €628,432/QALY
SA 10
(5 years time horizon)
Incremental cost €85,264 €104,049
Incremental effectiveness 0.727 QALY 0.088 QALY
ICER €117,326/QALY €1,181,371/QALY
SA 11
(10 years time horizon)
Incremental cost €157,243 €189,227
Incremental effectiveness 1.393 QALY 0.176 QALY
ICER €112,892/QALY €1,073,413/QALY
SA 12
(15 years time horizon)
Incremental cost €217,757 €257,070
Incremental effectiveness 2.016 QALY 0.268 QALY
ICER €108,029/QALY €960,222/QALY
ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life years; SA: sensitivity analysis. FG SSA: first-generation somatostatin analogues (octreotide,
lanreotide).
Bold values are used to highlight ICER for each alternative.
Figure 2. Survival curves for each treatment alternative. FG SSA: first-generation
somatostatin analogues (octreotide, lanreotide).











Pegvisomant 629,188 2,400 624,188 633,296
Pasireotide 643,814 701 642,496 645,215
FG SSA 250,668 581 249,573 251,843
Effectiveness
(QALYs)
Pegvisomant 14.495 0.393 13.676 15.168
Pasireotide 10.811 0.094 10.634 10.999




86,042 4,628 75,206 104,634
Pasireotide vs. FG
SSA
549,636 1,275 435,303 730,321
ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life years; FG SSA:
first-generation somatostatin analogues (octreotide, lanreotide). SD: standard
deviation; 95% CI: 95% confidence interval.
Bold values are used to highlight ICER for each alternative.
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According to the sensitivity analyses, applying a diabetes
disutility value of −0.23 (SA 6), increased pasireotide ICER to
€1,051,411/QALY (Table 5). In contrast, when control of IGF-1
levels was used to assess the efficacy of pasireotide (SA 4), its
ICER decreased to €354,068/QALY (Table 5).
In both comparisons, increasing the time horizon (SA 10–12)
resulted in a decrease in ICERs (Table 5).
3.2. Survival curves
Figure 2 shows the survival curves with the evolution of the
simulated cohort according to the treatment alternatives
analyzed.
3.3. Probabilistic sensitivity analyses
The probabilistic sensitivity analyses showed a mean
ICER of €86,042/QALY (95% CI [€75,206-€104,634/QALY])
for pegvisomant versus FG SSA and a mean ICER of
€549,636/QALY (95% CI [€435,303-€730,321/QALY]) for
pasireotide versus FG SSA (Table 6). These results are con-
sistent with the abovementioned results.
Figure 3 shows the incremental cost-effectiveness plane
of the 1,000 simulations performed for each comparison.
4. Discussion
Transsphenoidal surgery is the first-line treatment for most
patients with acromegaly. In patients with persistent disease
after surgery, FG SSA are indicated as first-line pharmacological
treatment [4,9]. If there is an inadequate response, contraindi-
cation or lack of tolerance to FG SSA, treatment with pegviso-
mant [4,7,9], or with the recently approved pasireotide, is
recommended (second-line pharmacological treatment) [8,9].
In patients not fully controlled with FG SSA, it is important
to take into account not only the efficacy and safety data from
pivotal clinical trials, but also to the cost-effectiveness evi-
dence to support the decision-making process in the selection
of treatment alternatives. For this purpose, we evaluated the
cost-effectiveness of pegvisomant or pasireotide treatment
a) Pegvisomant vs. FG SSA 
b) Pasireotide vs. FG SSA 
Figure 3. Incremental cost-effectiveness plane and confidence ellipses of the 1,000 simulations performed in the probabilistic sensitivity analyses of pegvisomant vs.
FG SSA (a) and pasireotide vs. FG SSA (b). ICER: Incremental cost-effectiveness ratio. QALY: quality-adjusted life years. FG SSA: first-generation somatostatin
analogues (octreotide, lanreotide).
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compared to FG SSA (octreotide and lanreotide) treatment
from the perspective of the Spanish NHS.
The results of this model showed that the use of pasireo-
tide versus FG SSA had an ICER six times greater than the use
of pegvisomant versus FG SSA (€85,869/QALY vs. € 551,405/
QALY) (Table 4). This difference in ICERs was mainly driven by
the incremental effectiveness (4.41 QALYs for pegvisomant
vs. FG SSA and 0.71 QALYs for pasireotide vs. FG SSA), with a
slightly lower increase in costs with pegvisomant (€378,597
vs. FG SSA) than with pasireotide (€393,151 vs. FG SSA) (Table
4). This difference is consistent with a higher survival and
diseases control rates with pegvisomant treatment (Figure 2
and Table 1).
The results of the sensitivity analyses confirmed the robust-
ness of the model (Table 5). In general terms, medication costs
had the greatest influence on the results. Thus, the increase in
pegvisomant or pasireotide doses by dose titration consider-
ably increased both ICERs, due to the increase in medication
costs (Table 5). Similarly, when only octreotide was considered
as FG SSA, both ICERs increased, since octreotide is less expen-
sive than lanreotide (Table 5).
It should be noted that besides the higher cost of pegviso-
mant relatively to pasireotide, the total cost of pasireotide is
higher than the cost of pegvisomant. This is mainly driven by
the cost of comorbidities (due to lower efficacy) and adverse
event management (especially hyperglycaemic adverse event)
with pasireotide. A recent study has also suggested this possi-
bility [34]. Indeed, both treatments have differential effects in
glucose homeostasis: pasireotide has been found to cause,
compared to FG SSA, increased fasting plasma glucose (FPG)
and glycated hemoglobin (HbA1c), thereby causing a higher
incidence of drug-related hyperglycaemic adverse events [10].
In contrast, pegvisomant has favorable effects on glucose meta-
bolism, since it improves insulin sensitivity, decreases FPG,
improves glucose tolerance and decreases HbA1c levels [35].
The results from our model show that treatment with
pegvisomant or pasireotide would not be cost-effective com-
pared to FG SSA, since the accepted efficiency threshold set at
€25,000/QALY would be exceeded [36]. However, the use of
the conventional efficiency threshold for the evaluation of
orphan medicinal products is questionable and under debate
[37–39]. Their higher acquisition costs and the difficulties in
assessing their long-term efficacy mean that orphan drugs are
not really comparable to other medicinal products using cost-
effectiveness thresholds which are usually employed.
It is important to note the changes in the treatment of
acromegaly in recent years. According to data from the French
registry [40], which evaluates the evolution of the management
of acromegaly over the last three decades, the number of cured
patients after surgery has barely changed while the percentage
of patients with a controlled disease by medical treatment has
increased. Therefore, nowadays the majority of acromegaly
patients can achieve an adequate control of the disease through
progressive treatment. However, therapeutic choices may deter-
mine the time needed to reach control and the cost-effective-
ness of patient management. Second-line treatments are more
expensive than FG SSA (Table 4); however, their use is needed
and recommended in guidelines to control the disease and
reduce mortality and comorbidities. Besides, maintaining a treat-
ment in resistant patients has an important associated cost and
little benefit. This analysis shows that maintaining FG SSA treat-
ment in patients resistant to this therapy has a cost of €250,650,
with an effectiveness of 10.1 QALYs (Table 4).
Several studies have been conducted to assess the cost of
acromegaly treatment. Studies on the analysis of preoperative
treatment to improve the results of surgery have suggested that
this strategy is cost-effective [41]. In 2004, Didoni et al. conducted
a study in 134 Italian patients over a period of 7 years [42]. The
costs of hospitalization, specialist visits, and drugs for comorbid-
ities were €7,968 per year for controlled patients and €12,533 per
year for uncontrolled patients [42]. A Spanish study evaluated the
cost in 11 consecutive patients with invasive macroadenoma in
2007 and established it to be between €7,072 and €9,874 per
patient per year [43]. In other study, the mean cost per patient per
year in 53 Canadian patients with acromegaly during a mean
follow-up of 49 months was $8,111 [44]. Valentim et al. [45]
conducted a cost-effectiveness study of octreotide LAR and lan-
reotide SR in Brazil, and found that octreotide LAR was more cost-
effective than lanreotide SR. In Spain, Roset et al. [46] analyzed
treatment costs in 74 patients with acromegaly between 2005 and
2007: the mean annual cost per patient was €9,668. The cost of
patients treated with surgery alone was €2,501 per year compared
to €9,745 per year for patients receiving medical treatment alone
[46]. In cases where both treatments were required, the annual
cost varied from €10,866 and €12,364 [46]. Recently, two systema-
tic reviews have been published on the cost-effectiveness of
pharmacological treatments for patients with acromegaly that
includes the abovementioned studies and conclude that cost-
effectiveness analyses of second-line treatments were controver-
sial and had important limitations [47,48].
In all the studies considered, pharmacological treatment was
the variable with the deepest impact in total direct costs. It was
estimated that pharmacological treatment could account for 71%
of the direct costs of the disease [46]. It should be noted that
comorbidity costs are always higher in uncontrolled patients
than in controlled patients [42,46]. Most of the studies do not
perform an exhaustive comparison between the different treat-
ments, so there may be relevant aspects of the direct and indirect
costs that are not considered [49].
Since this model is based on efficacy data from separate
clinical trials (with differences in the inclusion criteria, follow-
up periods or in the control groups) the results should be
confirmed by randomized clinical trials in which both alterna-
tives are compared directly, and also in clinical practice (i.e. real-
world data). Among the limitation of the study, the crossover of
the treatment with pasireotide to pegvisomant or vice versa has
not been analyzed because there are no data from clinical trials
to support the modeling of this possibility. In addition, the cost
estimate of this model only considers the direct costs of the
disease due to the lack of data on indirect costs. Actual costs
may be significantly higher if indirect costs are taken into
account. No study in real-world evidence for pasireotide was
included in the analysis, since only a retrospective study of very
small sample size was available [50].
Currently, radiotherapy is considered an adjuvant treatment
for patients with recurrent or persistent tumors after surgery
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and for patients resistant or intolerant to medical treatments
[5,9] and, therefore, was not included in this analysis.
Combination therapy (i.e. pegvisomant + FG SSA, off label
use), although prescribed in clinical practice and recom-
mended in guidelines and consensus [5,9], was outside the
scope of this analysis. However, it would be interesting to
study their cost-effectiveness in future analyses [51].
Here, we present the first exhaustive analysis studying the cost-
effectiveness of second-line treatment in patients resistant to
FG SSA.
5. Conclusions
In conclusion, the proposed model shows that the ICER of
pasireotide compared to FG SSA was six times higher than
the ICER of pegvisomant vs. FG SSA. According to this analysis,
pegvisomant is the most cost-effective alternative in the treat-
ment of acromegaly in FG SSA-resistant patients for the
Spanish NHS.
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